IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors by Alshaker, Heba A & Matalka, Khalid Z
REVIEW Open Access
IFN-g, IL-17 and TGF-b involvement in shaping
the tumor microenvironment: The significance of
modulating such cytokines in treating malignant
solid tumors
Heba A Alshaker and Khalid Z Matalka
*
Abstract
Multiple innate and adaptive immune effector cells and molecules partake in the recognition and destruction of
cancer cells to protect against growing tumors, a concept that is known as cancer immunosurveillance.
Unfortunately, cancer cells are capable of avoiding this process by immunoselection of poorly immunogenic tumor
cells variants along with subversion of the immune system and thus shaping both the tumor and its
microenvironment. Cytokines represent part of the complex pattern of the immune response which can assist the
development of cancer as well as to eliminate it. Simultaneously, a large number of cytokines may be involved in
the complex interactions between host and tumor cells where this dynamic cross-talk, between tumors and the
immune system, can either regulate tumor growth or tumor growth, invasion and metastasis take place. In this
review, we are stressing on the interface between infiltrated immune cells and tumor cells with the emphasis on
the bidirectional activities of specific cytokines: IFN-g, TGF-b and IL-17 within the tumor microenvironment and
their role in shaping it. In addition, the significance of modulating such cytokines in favor of anti-tumor response is
discussed and merits the use of mixture of targeted modulators to overcome the network complexity of cytokines
in the tumor microenvironment.
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1. Introduction
The failure of the immune system to recognize and era-
dicate cancer cells may partly be a result of insufficient
immunological activation. It is now increasingly recog-
nized that the microenvironment plays a critical role in
the progression of tumors where immune-resistant
tumor variants are selected initiating the process of can-
cer immunoediting. Tumor-derived soluble factors can
impel various mechanisms for escape from immune
attack in the tumor microenvironment [1,2]. The tumor
microenvironment is a pivotal factor in the course of
carcinogenesis and is largely dependent on its interac-
tions with microenvironmental components in a bidirec-
tional way and consequently tumor progression or
regression [3,4].
The tumor microenvironment was lately recognized as
the product of a developing crosstalk between different
cells types. In addition to tumor cells, the tumor microen-
vironment is comprised of immune cells, fibroblasts, stro-
mal cells and the extracellular matrix [3]. Normal cellular
microenvironment can inhibit tumor cell proliferation and
cancer formation [4]. Contrariwise, as tissue becomes can-
cerous pathological interactions between cancer cells and
host immune cells in the tumor microenvironment and
lymphoid organs create an immunosuppressive network
that protects the tumor from immune attack leading to
tumor growth, progression as well as invasion and metas-
tasis which is basically due to a deranged relationship
between tumor and stromal cells [3-5]. In this review, we
are stressing on the interface between infiltrated immune
cells and tumor cells with the emphasis on the bidirec-
tional activities of cytokines mainly IFN-g,T G F - b and
IL-17 within the tumor microenvironment and their role
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cial role of modulating such cytokines that favor anti-
tumor activity and ultimately leads to eradicating solid
tumors.
2. Immune cells action within tumor
microenvironment
As surveillance cells in the tumor microenvironment, den-
dritic cells (DCs), natural killer (NK), and natural killer
T cells (NKT) have been shown to infiltrate tumors and
monitor the presence of novel antigen derived from
tumors [6]. DCs may be activated by danger signals
released from stressed or necrotic tumor cells which may
include cytokines, heat shock proteins, intracellular
nucleotides, and intact double-stranded DNA [6-8]. Acti-
vation and migration of DCs from the tumor site of anti-
gen capture to secondary lymphoid organs is crucial in the
initiation and amplification of immune response thereby,
triggering a maturation program that includes expression
of multiple costimulatory molecules and cytokines that
result in efficient priming of effector T cell responses and
beneficial antitumor immunity [7]. Remarkably, the cyto-
kines produced in the local microenvironment modulate
the type of response that will be generated. Conversely,
DCs at the tumor microenvironment, which possess an
immature phenotype, is not necessarily conducive to the
activation of antitumor immune responses due to tumor-
derived local immunosuppressive cytokines milieu as
transforming growth factor (TGF-b), and IL-10 and
growth factors as vascular endothelial growth factor
(VEGF) that may instead suppress or re-conditioning DCs
function and/or myeloid-derived suppressor cells
(MDSCs) [7,9]. The latter would result in secreting more
of TGF-b to induce dampening of T cells and the augmen-
ted regulatory T (Treg) cell function, and ultimately indu-
cing anergy thus favoring tumor evasion. Inevitably,
efficient maturation of DCs at the tumor microenviron-
ment is pivotal for priming T cells responses and mount-
ing effective antitumor immunity [7,10-12].
MDSCs are heterogeneous population of myeloid
derived cells of immature in nature. MDSCs have the abil-
ity to suppress T cell responses, cytokine production, and
promote tumor angiogenesis and metastasis [9,11]. Nor-
mally these myeloid-derived cells are located in the bone
marrow differentiate to mature granulocyte, monocytes/
macrophages, or dendritic cells, and only 0.5% of periph-
eral blood mononuclear cells remains immature. In cancer
condition, however, their differentiation step is blocked,
proliferate and expand into MDSCs leading to a negative
impact on the immune system as a whole and more speci-
fically in the tumor microenvironment. MDSCs expand
systemically in mice (CD11b+GR1+) with transplantable
tumors or spontaneous tumors and in the peripheral
blood of patients (CD11+CD14-CD33+) with different
types of cancer. The induction and expansion of MDSCs
is initiated by factors and cytokines produced by tumor
stromal cells and activated T cells [9,11]. These factors
and cytokines that induce MDSCs are usually driven by
chronic inflammation. For instance, prostaglandin E2,
cyclooxygenase 2, IL-6, colony stimulating factor and
VEGF were found to induce the differentiation of CD11b
+GR1+ MDSCs from bone marrow stem cells of mice,
whereas COX-2 inhibitors or IL-1 deficient mice delayed
tumor progression suggesting partial mediation of MDSCs
by PGE2 and/or IL-1 [9,11,13]. These studies suggest that
inflammation promotes tumor progression through the
induction of MDSCs that block immune surveillance and
anti-tumor activity. MDSCs can directly affect T cell func-
tions via cell-cell contact i.e. MHC-restricted and antigen-
specific as well as indirectly through by suppressing CD4+
and CD8+ T cells, and inducing Treg cells [9,13]. However
the latter two mechanisms depends on the subpopulation
of MDSCs infiltrated in the tumor microenvironment with
their produced cytokines (e.g. IL-10, TGF-b) or factors
(e.g. nitric oxide, arginase, proxynitrate) [9-13].
In the course of tumor mass, infiltration of NK cells
into human neoplasm’s appears to correlates with a bet-
ter prognosis whereas low numbers of NK cells in
advanced human neoplasms indicate that NK cells do
not normally home efficiently to malignant tissues [14].
The crosstalk between NK cells, DCs, and T cells initiates
and sustains immune responses against tumors [15]. In
this process NK cells provide early and important sources
of IFN-g production as they might be the first to recog-
nize developing tumors and thus producing the initial
levels of IFN-g [16]. IFN-g secreted at the tumor site by
NK cells and NKT (type 1; invariant NKT) augments
MHC expression on tumor cells increasing their immu-
nogenicity which in turn can induce tumor cell death [1].
NK cells not only operate in early stage of tumor devel-
opment but also act as a helper in priming process of
CD8
+ and Th1 cells by producing IFN-g. Likewise, NK,
NKT (type 1 NKT), and gδT cells are regarded as major
sources of IFN-g during the early phase of tumor devel-
opment, whereas CD4
+ and CD8
+ T cells may become
additional sources as adaptive immunity evolves [17].
However, type II NKT cells were found to promote
tumor progression by producing IL-13 which induces
MDSCs accumulation and blocks their differentiation
[18].
Growing body of evidence indicates that tumor-specific
CD4
+ T cells and there subtypes (Th1, Th2, Treg or Th17)
are directly involved in mediating in vivo tumor regression
or evasion, as well as CD8+ T cells [19] (Table 1). Each of
the latter cell subtype is regulated by a different signal
transducer and activator of transcription (STAT) and tran-
scription factor and secretes unique repertoires of cyto-
kines that mediate their responses as well as they possess a
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and diseased conditions (Table 1). In addition, naïve
T helper cells (Th0) also were found to be a major cell of
tumor infiltrating lymphocytes (TIL) [20]. These Th0 cells
may produce IL-2, IFN-g as well as IL-4 and may evolve in
the tumor microenvironment depending on the danger sig-
nals provided in such environment [20,21]. The latter
observation and the fact that cross regulation of Th1 and
Th2 subsets occur through cytokine network has also been
observed in TIL and peripheral blood of patients with
other tumors [22]. Proportions of Th1 cells identified on
the basis of intracellular production of IFN-g are markedly
reduced, whereas proportions of Th2 cells producing IL-4
are significantly elevated [23,24]. Likewise, T cells infiltrat-
ing human cervical carcinomas exhibit enhanced Th2 cyto-
kine profiles, particularly increased IL-4 and decreased
IFN-g production [25]. Th2 polarization is dependent
upon, and leads to, production of IL-4 which might have
direct immunosuppressive effects on CD8
+ T cells at the
tumor site. Furthermore, favoring Th2 development pro-
motes tumor immune evasion leading to detrimental anti-
tumor response [26,27]. Meanwhile, STAT1-deficient mice
displayed an increase in Th2 polarization due to the block
in IFN-g signaling, and were more susceptible to tumor
development [28]. These results indicate the importance of
polarizing TIL to Th1 cells to control and induce regres-
sion of solid tumor.
Currently, Th17 cells have been shown to play impor-
tant roles in inflammation and autoimmune diseases, but
their exact roles in tumor immunity are still meager and
contradictory [29,30]. Some studies, however, detected
low number of Th17 cells in several types of tumor such
as ovarian cancer, [31], non-Hodgkin’s lymphoma [32],
and HER2 positive breast cancer patients [33]. For
instance, the levels of tumor-infiltrating Th17 cells were
reduced in a group of ovarian cancer patients with more
advanced disease and seemed to positively anticipate the
outcome [31]. Th17 cells were able to contribute to
protective human tumor immunity through recruiting
effector cells to the tumor microenvironment [34].
Furthermore, tumor-specific Th17-polarized cells can
eradicate large established melanoma in mice and were
inversely correlated with Gleason score in prostate cancer
patients [34,35]. A possible explanation lies in that Th17
CD4
+ T cells can be unstable and may evolve into IFN-g-
producing Th1-like cells capable of promoting tumor
destruction. This effect also seems to be contingent on
IFN-g, as blocking antibodies prevented Th17 cell trans-
fer from causing tumor regression [34].
Since Th17 cells are considered potent inducers of auto-
immunity through the promotion of tissue inflammation
and the mobilization of the innate immune system [19],
the resulting inflammatory mediators may contribute to
tumor progression by upregulating immune suppressive
cells of the adaptive and innate immune systems. Substan-
tial evidence indicates that the inflammatory reaction at a
tumor site can promote tumor growth and progression
[36,37]. Tumor-associated inflammatory cytokines such as
IL-6 and tumor necrosis factor (TNF)-a probably regulate
Th17 cells in the tumor microenvironment of ovarian can-
cer mouse model [38]. Also, tumor-activated monocytes
(TAM) promote expansion of Th17 cells through secreting
a set of key proinflammatory cytokines, such as IL-1, in the
peritumoral stroma of hepatocellular carcinoma tissues
[39] and ovarian cancer patients [31]. Notably, Kryczek et
al. reported the prevalence of Th17 cells in peripheral
blood and tumor microenvironment in both human and
mice [40]. Elevated proportion of Th17 cells were also
detected both in the peripheral blood and in the tumor-
draining lymph nodes of patients with gastric cancer,
which were associated with clinical stage [41]. Th17 cells
were also suggested as a prognostic marker in hepatocellu-
lar carcinoma [42] suggesting that Th17 cells can also play
an active role in tumor pathogenesis. Nonetheless, whether
Th17 cells play the same roles in the different types and
stages of cancers remains to be determined [29,30].
Table 1 CD4
+ T lymphocytes and their functions in relation to transcription factors, priming and secreted cytokines in
tumor progression or regression
Th1 cells Th2 cells Th17 cells CD4
+CD25
+ Treg
Priming cytokines IL-12
IFN-g
IL-4 TGF-b and inflammatory cytokine (IL-1, IL-21, IL-6, TNF-a and IL-23) TGF-b1
Transcription factors T-bet
STAT1
GATA3
STAT6
RORgt
RORa
STAT3
Foxp3
SMAD
Major secreted
effector cytokines
IL-2
IFN-g
TNF-a
IL-4
IL-5
IL-13
IL-17A (IL-17)
IL-17F
IL-21
IL-22
TGF-b1
IL-10
Role in tumor
microenvironment
Help CD8
+
T cells
Suppress CD8
+ T cells
Recruit Th1 effector T cells/Suppress CD8
+ T cells and promote early
growth in the inflammatory environment?
Suppress CD4
+ and
CD8
+ T cells
Outcome Tumor
regression
Tumor
progression
Tumor regression/progression? Tumor progression
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+CD25
+ Treg cells have
emerged as being particularly critical for the maintenance
of immunologic tolerance [43]. The cross-talk between
Treg cells and targeted cells, such as APCs and T cells, is
crucial for ensuring suppression by Treg cells in the
appropriate microenvironment by soluble factors and
direct cell-cell contact [44]. For instance, Treg cells inhibit
DCs function through binding of CTLA-4 to CD80/86
[43-46] and IL-12-Th1 cell activation by producing TGF-b
and IL-10 [45,46]. Notably, elevated proportions of CD4
+CD25
+ Treg in the total CD4
+ T cell populations are pre-
sent in the tumor microenvironment of various types of
cancer where they mediate immune suppression via down
regulating the functions of CD4+, CD8+, NK and NKT
cells [47-49]. For instance, CD4
+CD25
+ Treg cells enhance
susceptibility to 3-methylcholanthrene (MCA)-induced-
tumorigenesis [48] and depletion of CD4
+CD25
+
Treg cells reduced tumor growth of MCA-induced fibro-
sarcomas [49].
Despite the disparate functions of Treg and Th17 sub-
sets, both have been shown to be dependent on TGF-b for
their differentiation [50]. Therein, TGF-b induces the Treg
specific transcription factor Foxp3. However, addition of
IL-6 to TGF-b enhances differentiation of Treg cells into
Treg/Th17 cells [29,50]. Thus, TGF-b in the absence of
inflammatory cytokines will induce Foxp3
+ Treg cells dif-
ferentiation [50-52]. In addition, Treg/Th17 cells under
the influence of IL-21 and IL-6 can differentiate into Th17
[29]. Moreover, the cytokines that promote Th17
responses significantly counteract the activation and func-
tionality of the Tregs [29,51,52]. Thus, the cross-talk
between immune cells within the tumor microenviron-
ment involves interactions between expressed receptors
on cells, types of cytokines and chemokines produced
which are dependent on the stimulus or stimuli present in
such environment. Such cross-talk leads to the outcome of
t u m o ro c c u r r e n c eo rn o - t u m o rp r o m o t i o n .T h e r e f o r e
modulating such interactions and cytokines would be a
target therapeutic tool to enhance the immune response
against the tumor cells that results in eradicating them.
3. TGF-b, IL-17 and IFN-g expression and activities
within the tumor microenvironment
3.1 IFN-g
IFN-g is the signature cytokine produced by Th1 cells but
is also derived from CD8
+ T cells, gδ T cells, NKT, and
NK cells [16,17]. IFN-g exerts its biologic effects by inter-
acting with an IFN-g receptor (IFNGR) 1 and IFNGR2
[53] resulting in activating Janus tyrosine kinase (JAK)-
STAT signaling pathway which ultimately leads to phos-
phorylation of two STAT1 molecules followed by their
dimerization and nuclear translocation [54].
IFN-g is a cytokine that is well recognized to play a
central role in coordinating tumor immune responses
(Table 2). Although, few studies associated IFN-g with
tumor development via MDSCs activation and Th17
associated inflammation [55], plenty of studies have been
conducted to dissect the mechanism by which IFN-g
mediates tumor rejection [56]. For instance, mice lacking
IFN-g receptors or STAT1 deficient mice developed
tumors more rapidly and with higher frequency than wild
type mice following a challenge with MCA [57]. An
unequivocal demonstration of cancer immune surveil-
lance is that tumor suppressor function of the immune
system is critically dependent on the actions of IFN-g
which along with lymphocytes collaborate to protect
against development of carcinogen-induced sarcomas
and spontaneous epithelial carcinomas [56-58]. In tumor
cells, IFN-g upregulates the expression of the MHC class
I antigen-processing and -presentation pathway, thereby
enhancing tumor cell immunogenicity and facilitating
tumor recognition and elimination by lymphocytes
[58-60]. Actually, IFN-g displays an essential role for
tumor responsiveness by regulating the migration of T
cells into tumor tissue [28,60]. The IFN-g produced by
tumor-infiltrating T cells might play two distinct roles in
antitumor activity: activation of antitumor T cells and
direct tumoricidal activity by generating inducible nitric
oxide synthetase [57-61].
Studies of the benefaction of IL-12 to antitumor immu-
nity provide further insight into the physiologically rele-
vant stimuli for IFN-g production to enhance antitumor
immunity [61]. Cytokines as IL-12 can stimulate IFN-g
production from TH1 cells, gδ T cells, NK cells, NKT cells
[16,17,62-64]. IFN-g produced by IL-12-activated tumor-
infiltrating CD8
+T cells directly induced apoptosis of
mouse hepatocellular carcinoma cells [65,66]. In addition,
IFN-g has a profound impact on solid tumors growth and
metastasis and appeared to play an early role in protection
from metastasis [67,68]. Developing solid tumors demand
new blood vessel creation in order to grow. Partially, this
occurs through both: induced outgrowth of the preexisting
vasculature and de novo recruitment of vascular cell pre-
cursors from the circulation [69]. Th1 cells can impair
tumor angiogenesis either directly by inhibiting endothelial
cell proliferation through IFN-g or indirectly through
induction of antiangiogenic chemokines such as chemo-
kine (C-X-C motif) ligand (CXCL)9 and CXCL10 leading
to both angiostasis in and around the tumor and chemoat-
traction of immune effector cells into the tumor site
[61,70]. Moreover, IFN-g can antagonize the production of
immunosuppressive cytokines such as TGF-b and IL-10
which can promote the development of otherwise highly
immunogenic tumors, improves the establishment of an
effective antitumor memory immune response, and thus
controls ongoing tumor growth [66]. However, recent stu-
dies have shown that Eriobotrya japonica hydrophilic
extract (EJHE) induced IL-12, IFN-g and TNF-a in vivo
Alshaker and Matalka Cancer Cell International 2011, 11:33
http://www.cancerci.com/content/11/1/33
Page 4 of 11and in vitro more than IL-10 [71], and increased IFN-g
levels, decreased TGF-b levels but did not change IL-17 in
spleen of normal mice [72]. Even though continuous
administration of EHJE increased IFN-g levels in the
tumor microenvironment as well as TGF-b and IL-17, the
survival of Meth-A fibrosarcoma bearing mice was signifi-
cantly increased [72]. This indicates the complexity of the
tumor-infiltrated immune cells such as MDSCs, Treg, and
TH17 as well as their differentiation stages, immune-cyto-
kine network and the type of tumor and its sensitivity to
anti-tumor/pro-tumor cytokines.
3.2 IL-17
IL-17 or (IL-17A) is the original member of IL-17 family
which further includes IL17B, IL17C, IL17D, IL17E (also
called IL-25), and IL17F which displays the highest
degree of homology with IL-17A [73,74]. IL-17 is the sig-
nature cytokine of a unique lineage of CD4
+ Tc e l l s
termed Th17 [73]. Additional cellular sources of IL-17A
include gδT cells, CD8
+ T cells, neutrophils and eosino-
phils [73,74]. IL-17 is also produced by NKT cells upon
TCR stimulation [74]. IL-17 binds to and signals through
IL-17 receptor A (IL-17RA) which is widely expressed on
epithelial cells, endothelial cells and fibroblasts. The liga-
tion of IL-17/IL-17R results in the release of inflamma-
tory mediators like IL-1, IL-6, IL-8, IL-23, TNF-a and
several chemokines to further stimulate the inflammatory
cascade. Since inflammation is regarded as a promoter to
carcinogenesis [36], evaluating IL-17 in cancer develop-
ment is a necessity.
IL-17 secreting cells have been identified in many types
of human cancers and in murine models as well, however,
there are discrepant data on a possible role for IL-17 in
carcinogenesis as its precise role is still comparatively
poorly understood [29,30]. A series of reports have sug-
gested potent antitumor functions for IL-17 and IL-17
producing T cell subsets [29-35,75-77]. Antitumor activity
of IL-17 could be achieved by means of a T cell-dependent
mechanism as in an increased generation of specific CTLs
[75]. Transfection of IL-17 into Meth-A fibrosarcoma cell
lines was shown to augment the expression of both MHC
class I and II antigens, therefore inducing tumor specific
antitumor immunity [76]. Tumor growth and lung metas-
tasis were intensified in IL-17 deficient mice whereas in
vitro TGF-b and IL-6 polarized Th17 cells induced tumor
regression [77]. Similarly, IL-17 deficient mice were more
susceptible to developing lung melanoma than wild-type
mice, a phenotype that was blocked by adoptive transfer of
tumor specific Th17 cells [78]. Transferred Th17 cells pre-
vented tumor development and exhibited stronger thera-
peutic efficacy, than Th1 cells, fostered immune
surveillance by CD8
+ CTLs and DCs implying that the sti-
mulation of IFN-g production by IL-17 is needed for IL-17
exerted antitumor response in IL-17 deficient mice [78].
Notwithstanding, other reports have suggested potent
protumor functions for IL-17 and IL-17 producing T cell
subsets. Whilst IFN-g disrupts developing tumor’s vascula-
ture [60], it is established that IL-17 is as an angiogenic
factor that act on endothelial, stromal and tumor cells. IL-
17 stimulates the migration of vascular endothelial cells
in vitro and elicits vessel formation in vivo to induce
tumor vascularization and promote tumor growth [79-81].
Coincidently, defects in IFN-gR are associated with
increased tumor growth whereas IL-17R-deficient mice
display reduced tumor development. Blockade of IL-17
even reverses the susceptibility of IFN-gR
-/- mice to tumor
development indicating that IL-17-mediated responses at
tumor sites promote tumor development [81]. Addition-
ally, the latter report also showed that a defect in IL-17R
reduces IFN-g production by T cells and that tumor
growth is inhibited in IL-17/IFN-gR double-knockout
mice suggesting that IFN-g appears to play a minor role in
IL-17-mediated regulation of tumor development [82].
This observation is also confirmed by a previous report
showing inhibition of tumor development in IL-17/IFN-g
double-knockout mice [83]. It has to be mentioned also
Table 2 IFN-g, IL-17 and TGF-b effects in the tumor microenvironment
Cytokine Secreting
cells
Cytokine effects
IFN-g CD4
+ Th1
CD8
+ T
NK
NKT
gδ T cells
Positive effects on tumor immune surveillance:
Directs anti-proliferative and cytotoxic effects
Upregulates MHC expression on tumor cells
Inhibits angiogenesis
Antagonizes suppression by tumor-derived TGF-b
IL-17 Th17
gδ T cells
Positive and negative effects on tumor immune surveillance, depending on tumor context and model:
Suppresses tumor progression by enhancing antitumor immunity, or promote tumor progression by an increase in
inflammatory angiogenesis?
TGF-b1 CD4
+CD25
+
Foxp3
+
Treg
Th17
Negative effects on tumor immune surveillance:
Remodeling of tumor matrix and stromal cells
Promotes angiogenesis
Induction of Treg cells development
Inhibits development, proliferation, and function of both the innate and the adaptive immunity
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MDSCs tumor infiltration [82], and systemic administra-
tion of IL-17 promoted tumor growth, enhanced MDSCs
and reduced CD8 T cells tumor infiltration [82]. Further-
more, it has been shown recently in a spontaneous model
of intestinal tumorigenesis (driven by a heterozygote
mutation in the tumor suppressor gene denomatous poly-
posis coli) that the ablation of IL-17 leads to inhibition of
tumor development [84]. Additionally, IL-17 promoted
the growth rate and tumorigenicity of human cervical
tumors transplanted into athymic nude mice [85]; knock-
down of the IL-17 receptor in 4T1 mouse mammary can-
cer cells decreased tumor growth in vivo [86]; and IL-17
depletion delays development of chemically induced papil-
lomas [55]. Remarkably, these effects seem to be driven by
a pathway of IL-17 inducing IL-6 production by both neo-
plastic and stromal cells, which successively leads to acti-
vation of STAT3 [83]. Such activation of STAT3 in tumor
cells and tumor-associated inflammatory cells plays a criti-
cal role in tumor progression by augmenting tumor survi-
val and tumor angiogenesis, and suppressing antitumor
immunity [87]. Seemingly, not merely STAT3 is involved
but also a number of inflammatory cytokines does play
critical roles in this process and many reports indicate that
IL-17 in the context of inflammations exerts tumor pro-
moting effects [38,87].
Proinflammatory cytokine as IL-23 is an important
cytokine for the expansion and survival of Th17 cells
[88]. IL-23 demonstrated to be an important link
between tumor-promoting and proinflammatory pro-
cesses. IL-23p19 mRNA was upregulated in significant
manner in the majority of cancer samples from various
organ types, comprising colon, ovarian, lung, breast, and
stomach cancers as well as melanoma [88]. STAT3 sig-
naling within the tumor microenvironment induces the
protumor cytokine, IL-23, while inhibiting a central anti-
tumor cytokine, IL-12, thereby shifting the balance of
tumor immunity toward carcinogenesis [88,89]. In the
course of the tumor microenvironment, TNF-a enhanced
tumor growth via the inflammatory cytokine IL-17 in a
mouse model of ovarian cancer and in patients with
advanced cancer [38]. Moreover, a set of key cytokines
profile (IL-1b,I L - 6 ,T N F - a,a n dT G F - b) was detected in
ovarian tumor cells, tumor-derived fibroblasts, and
APCs, which formed a cytokine milieu that regulated and
expanded human IL-17-producing Th17 cells [90] sug-
gesting that these inflammatory cytokines within the
tumor microenvironment can provide a favorable niche
for developing the unstable Th17 cells and potentially
directing them into a dangerous feedback loop.
3.3 TGF-b1
TGF-b i sam e m b e ro fal a r g ef a m i l yo fd e v e l o p m e n t a l
conserved proteins. Three closely related isoforms have
been identified of this family including TGF-b1, TGF-b2
and TGF-b3 [91]. TGF-b1i st h ep r e d o m i n a n ti s o f o r m
expressed in the immune system and lymphoid organs
and is essential for maintaining T cell homeostasis, Treg
cells and effector cells function and carcinogenesis [91].
TGF-b binds type I and II TGF-b receptors causing phos-
phorylation of the downstream mediators SMAD 2 and 3.
The phosphorylated SMAD2 and 3 combine to SMAD4
and enter the nucleus to modulate gene expression.
TGF-b signaling is contextual, depends on the cell type,
and has both positive and negative effects on cancer.
Specifically, in cancer TGF-b exerts a perplexed role. Initi-
ally, it acts as a tumor suppressor since it induces apopto-
sis and inhibits the growth of cells [91,92]. In mice,
transgenic expression of TGF-b1 in mammary gland pro-
moted growth arrest and in some settings enhanced apop-
t o s i s[ 9 1 ] .H o w e v e r ,c h a n g e si nT G F - b signaling often
correlate with tumor stage and rate of progression [91,92].
At later stages of tumor progression, TGF-b a c t sa sa
tumor promoter. Seemingly at this stage cancer cells pro-
tect themselves and tend to acquire increasing resistance
to ignore TGF-b growth inhibitory signals which is an
important reason for the shift from being a tumor sup-
pressor to a tumor promoter. Subsequently, cancer cells
start secreting non-physiological levels of TGF-b in an
autocrine and paracrine manner which may affect the dif-
ferentiation of the tumor cells and the surrounding cellu-
lar environment, respectively, leading to development of
the tumor and metastasis in an immunosuppressive envir-
onment that is rich in TGF-b [93]. Deletion of the type II
TGF-b receptor gene (Tgfbr2) in mammary carcinomas
results in the recruitment of Gr-1
+CD11b
+ MDSCs that
directly promoted tumor metastasis through enhanced
metalloproteinase and TGF-b production [94].
In the context of malignant niche, TGF-b induces
epithelial transition that in turn converts cancer cells into
invasive cells. Tumor-derived TGF-b causes remodeling
of the tumor matrix: by acting on stromal fibroblasts;
inducing the expression of mitogenic signals towards the
carcinoma cells; and by promoting angiogenesis through
stimulating VEGF and other angiogenic factors produc-
tion which correlates to increased invasiveness and
metastasis [91-95]. Additionally, suppression of the
immune system by TGF-b also contributes to its tumor
promoting effects. In the perspective of the complex
interplay between the immune system and tumor micro-
environment, TGF-b is an immunosuppressive cytokine
that function at several levels in the tumor microenviron-
ment which also encompasses reduction in the amount
of antigen presentation by DCs [12-14], reduction in the
proliferation of T cells (Th1, Th2 and CTL), suppression
of NK cells cytotoxic activity, and stimulation of Treg
cells proliferation thus impeding immune surveillance of
the developing tumor [91,92]. Nam and his colleagues
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bed contributes to a local cytokine milieu that can sub-
vert CD8
+ T cell differentiation or expansion down a
proinflammatory, IL-17-secreting path [86]. Moreover,
knockdown of the IL-17 receptor in 4T1 mouse mam-
mary cancer cells enhanced apoptosis and decreased
tumor growth in vivo confirming that tumor cells evolved
to use IL-17 as a survival factor as one of the conse-
quences of TGF-b overexpression [89].
Being one of the most commonly used drugs in cancer
chemotherapy, Doxorubicin, is a DNA-damaging drug
that possesses strong antineoplastic activity. Doxorubicin
specifically inhibited TGF-b-signaling in human lung ade-
nocarcinoma A549 cells by blocking TGF-b1-induced acti-
vation of SMAD3-responsive CAGA12-Luc reporter while
other drugs like Cisplatin or Methotrexate did not alter
activation of CAGA12-Luc reporter under the same condi-
tions suggesting that that such inhibitory effect could be a
novel mechanism of Doxorubicin action towards tumor
cells [96]. Measurement of IFN-g and IL-17 were not
reported in the latter work, however, molecular targeting
of TGF-b production or disruption of the TGF-b pathway
could not only improve host immunosurveillance but also
inhibit tumor progression by upregulation of IFN-g,a n d
provide additional therapeutic options through manipula-
tion of IL-17 levels. Moreover, strong evidence suggests
that therapeutic intervention in TGF-b signalling via small
molecule, antibody or antisense TGF-b antagonists are
needed to fulfill one important aspect of treating solid
malignant tumors [92,97].
4. The paradigm role of TGF-b, IL-17 and IFN-g
within tumor microenvironment
Since the circular nature of the relationship between
inflammation and cancer has proven to be evident, it is
important to emphasize the following generalizations;
inflammation can cause cancer; inflammation can cause
mutation; mutation can cause inflammation; mutation can
cause cancer; cancer can cause inflammation; and inflam-
mation can suppress cancer [98]. In addition, inflamma-
tion can modulate the immune response to enhance
tumor growth [17,21,26,40]. Since TGF-b is conventionally
regarded as an anti-inflammatory cytokine whereas IFN-g
and IL-17 are considered proinflammatory cytokines, the
paradigm role of these cytokines is complex in cancer
immunology and tumor microenvironment. TGF-b
demonstrates both tumor suppressor and oncogenic activ-
ities [92]. In the current paradigm, the suppressor activities
dominate in normal tissue. On the other hand, changes in
TGF-b expression and cellular responses during tumori-
genesis tip the balance in favor of its oncogenic activities
to drive malignant progression, invasion and metastasis
both in vitro and in vivo [92,99]. In fact, understanding the
roles of TGF-b produced from T cells, Treg, MDSCs and
even B regulatory cells within the tumor microenviron-
ment requires insight into the changing response patterns
of many interacting cell types [11,92,100,101]. For
instance, mutations in type II TGF-b receptor gene,
TGFBR2, are frequent in human colon cancer with micro-
satellite instability [102], and down regulation of TGF-b-
SMAD signaling pathway is associated with poor prog-
nosis in breast cancer patients [103]. Furthermore,
deletion of TGFBR2, in mammary epithelial cells results in
increasing chemokines that recruit further MDSCs [94].
These MDSCs secretes high levels of TGF-b and metallo-
proteinases [94]. In a tumor microenvironment, the latter
two enhances tumor growth and metastasis. In addition,
loss of TGFBR2 in fibroblasts or T cells leads to prostate
intraepithelial neoplasia and colon carcinoma [104]. These
data suggest controlling inflammation reduces tumorigen-
esis and inflammation in an established tumor enhances it
growth and metastasis. On the other hand, TGF-b,a sa
tumor promoter and considered to be pre-oncogenic, is
produced from many tumor types. For instance, TGF-b-
SMAD activity is usually high in aggressive gliomas [105].
Several studies showed the blocking TGF-b reduced
tumor progression through several parameters including
high infiltration of CD8+ T cells and suppression of Treg
and MDSCs [93,86,106].
Th17 cells differentiation requires TGF-b in humans
and mice as well. However, TGF-b alone is not sufficient
for the induction of Th17 in mice as it requires IL-6 plus
TGF-b [77,83,107,108]. Actually, the discovery that TGF-b
is a crucial cytokine for Th17 cell development suggested
that Th17 and Treg cell subsets share reciprocal develop-
mental pathways from uncommitted CD4
+ precursors
[50]. Moreover, there is a direct lineage relationship of
Th17 cells with Treg cells. Indeed, these two subsets
require TGF-b for lineage commitment and it is further
observed that there are direct interactions between the
lineage specific transcription factor Foxp3 of Treg and
RORgt of Th17. Further work showed that TGF-b signaled
in a concentration dependent manner to promote the
expression of both Foxp3 and RORgt. Foxp3 directly
bound to RORgt preventing Th17 differentiation; an effect
relieved by IL-6, IL-21 and IL-23, therefore confirming the
suppressive function of Foxp3 on RORgt [52]. Practically,
such interactions can’t be disregarded within local tumor
microenvironment but even still need to be fully further
investigated. A study has revealed that in parallel to high
levels of CD4
+Foxp3
+ Treg cells, IL-17
+ T cells including
CD4
+ Tc e l l sa n dC D 8
+ T cells were kinetically induced in
the tumor microenvironment in multiple mouse and
human tumors. Furthermore, IL-17
+ T cells demonstrated
a dynamic differentiation; Th17/Treg, Th17, and Th17/
Th1 in the tumor microenvironment thus providing new
insight of IL-17
+ T cells potential role in tumor immune
pathology and therapy [40].
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cells could express IL-17 that represents an early event in
the development of the inflammatory reaction within the
tumor microenvironment which may successively influ-
ence tumor phenotype and growth [29]. Ostensibly, IL-17
seems to be a pleiotropic cytokine, as other inflammatory
cytokines, with possible protumor or antitumor effects
which often depends on the immunogenicity and degree
of inflammation in the tumor itself [29,82]. Meth-A cells
transfected with the human IL-17 gene can induce tumor-
specific antitumor immunityb ya u g m e n t i n gt h ee x p r e s -
sion of major histocompatibility complex (MHC) class I
and II antigens; this antitumor immunity may be mediated
by CD4
+ and CD8
+ T cells [76]. On the other hand, using
IL-17 knockout mice, Wang et al. showed that disruption
of IL-17 reduced tumorigenesis and it was associated with
less STAT3 activation, STAT3-associated proliferative and
antiapoptotic gene expression, hyperplasia, and MDSCs
tumor infiltration within the tumor microenvironment
[83]. The latter results indicate the role of IL-17-STAT3
pathway in cancer-associated inflammation in the tumor
microenvironment. Furthermore, IL-17 up-regulated ela-
boration of a variety of proangiogenic factors by fibroblasts
as well as tumor cells revealing a novel role for IL-17 as a
CD4 or gδT cell-derived mediator as a tumor promoter by
inducing angiogenesis and tumor growth [80,83]. A recent
work showed that G-197A allele of the IL-17A gene pro-
moter was significantly associated with an increased risk
of subsequent development of intestinal-type gastric can-
cer upon its association with the progression of gastric
mucosal inflammation and the development of gastric
mucosal atrophy [109]. In addition, a very recent report by
Kryczek et al. [110] showed for the first time an IL-17+
regulatory T cells expressing FoxP3 (IL-17+Foxp3+CD4+
T cells) in the tumor microenvironment of inflammatory
tumors such as colon cancer as well as chronic inflamma-
tion tissue of the colon but not in renal cell carcinoma,
melanoma or ovarian carcinomas. The latter is supported
by the two stage skin carcinogenesis model using 7,12-
dimethyl benz(a) anthracene/12-O-tetradecanoylphorbel-
13-acetate (TPA)-induced pa p i l l o m aw h e r et h el a t t e r
upregalated IL-17 expression in the skin papilloma and
TH17 in the draining lymph nodes. Depletion or neutrali-
zation of IL-17 led reduced keratinocyte proliferation and
delayed papilloma development [55]. However, the latter
observations were also correlated with IFNg R deficiency
or neutralization of IFN-g and IFN-g response to induce
the expression of TNF-a,I L - 6 ,T G F - b during the papil-
loma promoting stage. This stresses that the differential
behavior of IL-17 within inflammatory versus non-inflam-
matory solid tumors and opens a new strategy for suppres-
sing these cells in inflammation-induced solid tumors via
down regulating SMAD3/4 and STAT3 signaling path-
ways. Similarly, it was found that in vivo inactivation of
genes that govern MDSCs accumulation, such as STAT3
and STAT6 restores T cell function and promotes tumor
regression [13].
The mouse prostate cancer cell line TRAMP-C2 secretes
TGF-b1 and show low MHC-I expression. Treatment with
IFN-g increased MHC-I expression and antagonized the
immunosuppressant activity of TGF-b [66]. Since IFN-g
and TGF-b show reciprocal antagonistic effects, treatment
of TRAMP-C2 with IFN-g not only restored MHC-I
expression but also improved the establishment of an
effective antitumor memory immune response and thus
the control of ongoing tumor growth [66]. In vitro, studies
with hepatic stellate cells demonstrate that TGF-b-depen-
dent activation of SMAD3/4 responsive reporter construct
was significantly decreased by IFN-g due to the fact that
IFN-g induced the activity of the SMAD7 promoter and
SMAD7 protein expression via STAT-1 signaling provid-
ing a novel approach for opposing profibrogenic activities
of TGF-b in liver cells and indicating a TGF-b antagoniz-
ing function by IFN-g [96].
Treatment of cancer is critically dependent on IFN-g
and it is ability to activate macrophages, T cytotoxic, NK
cells, and regulate MDSCS, Treg cells. However, IFN-g
relation to IL-17 and TH17 cells depending on the tumor
environment context and the stability of TH17 [55,110].
Nonetheless, the finding that IFN-g receptor knockout
mice exhibit severely impaired antitumor capability illu-
strated the importance of IFN-g in tumor immunity and
the induction of IFN-g via STAT1 activation and inhibi-
tion of STAT6 and 3. All in all, IFN-g is correlated with
several direct and indirect antitumor properties and tumor
responsiveness to IFN-g is necessary for IFN-g-dependent
inhibition of tumor angiogenesis by CD4
+ T cells.
5. Conclusions and future directions
It is clear that IFN-g,I L - 1 7a n dT G F - b are capable of
exerting multiple effects within tumor microenvironment
site, many of the exerted effects are contextual hence,
compelling further investigations in that regard along with
any attempt of their modulation that should be
approached with a definite knowledge of the initial level of
cytokines and their complex interaction with particular
type of tumors and the immune cells. Such knowledge
might better be enhanced through studying the gene
expression of cytokines and gene-expression signatures in
relation of type of infiltrating immune cells within the
tumor microenvironment.
Since in the tumor microenvironment the targeted cells
react differently in context with different stimuli, care
should be taken in the creation of therapeutic interven-
tions utilizing compounds that could stable the delicately
re-harmonized equilibrium that exists at the base of cyto-
kine network. Additional evidence for the criticality
of cytokines in cancer is their antagonistic efficacy as
Alshaker and Matalka Cancer Cell International 2011, 11:33
http://www.cancerci.com/content/11/1/33
Page 8 of 11aforementioned. Therefore, we propose that modulating
cytokines’ effects on immune response in the tumor
microenvironment are potential sources for a favorable
outcome (Table 3). For instance, immunomodulators that
have the capacity to induce IL-12 and IFN-g with novel
SMAD3/4 or STAT3 and STAT6 inhibitory molecules are
potential targeted mixtures of polarizing the beneficial
immune cells within tumor microenvironment. Further-
more, such mixtures with known chemotherapeutic agents
that are potentially selective would be more potent in
treating malignant solid tumors.
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